ANALYSIS: Leveling the Playing Field—The Role of Venture Capital in Hatch–Waxman Act Patent Litigation

As many in-house counsel for generic manufacturers will tell you in candid, off-the-record moments, the costs of funding Hatch-Waxman patent cases seem increasingly prohibitive to senior management, especially because at least half the time, the innovator patentee will either prevail or force the generic litigant into an economically unattractive settlement.

Department of Health and Human Services Panel Approves Report Endorsing Gene Patent Infringement Exception

A U.S. Department of Health and Human Services advisory committee Feb. 5 approved a final report that included a recommendation that an exception to…